| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
1 company
Nandabalan Krishnan is a Director, 10% Owner at BioXcel Therapeutics, Inc.. Recent SEC Form 4 filings include 1 buy and 8 sells.
Estimated insider holdings value: $71K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 | BTAI Bioxcel Therapeutics, Inc. | Director, 10% Owner | Sale+OE | 60,000 | $17.32 | $1,039,200.00 | -100% | -35.1% | -84.6% | |
| Jan 5, 2023 | BTAI Bioxcel Therapeutics, Inc. | Director, 10% Owner | Sale+OE | 60,000 | $22.01 | $1,320,875.99 | -85.0% | -23.3% | -87.4% | |
| Nov 11, 2022 | BTAI Bioxcel Therapeutics, Inc. | Director, 10% Owner | Sale+OE | 60,000 | $15.00 | $900,000.00 | -100% | +104.4% | -67.3% | |
| Jun 25, 2021 | BTAI Bioxcel Therapeutics, Inc. | Director | Sell | 473,250 | $30.83 | $14,589,492.98 | -5.2% | +3.1% | -61.0% | |
| Nov 29, 2018 | BTAI Bioxcel Therapeutics, Inc. | Director, 10% Owner | Buy | 1,000 | $4.92 | $4,915.00 | New | - | - |